Arcturus Therapeutics

Arcturus Therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/JoePayne_LanguageProficiency_V3_1.mp4?time=1638310588
arabic
(عربى)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/MaherA_LanguageProficiency_V3_1.mp4?time=1638310588
chinese
(中文)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_BelleBao.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/BelleBao_LanguageProficiency__V3_1.mp4?time=1638310588
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_HowardYu.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/HowardYu_LanguageProficiency_V3_1.mp4?time=1638310588
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_YurongGuo.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/YurongGuo_LanguageProficiency_V3_1.mp4?time=1638310588
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_XuefengGuo.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/XuefengGuo_LanguageProficiency_V3_1.mp4?time=1638310588
english
(British)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/MikeHodges_LanguageProficiency_V3_1.mp4?time=1638310588
farsi
(فارسی)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/01/NedaSafarzadeh_LanguageProficiency_V4.mp4?time=1638310588
french
(Français)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4?time=1638310588
german
(deutsch)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4?time=1638310588
hebrew
(עִברִית)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_NoaScott.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/NoaScott_LanguageProficiency_V3_1.mp4?time=1638310588
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_TamarGrossman.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/TamarGrossman_LanguageProficiency_V3_1.mp4?time=1638310588
hindi
(हिन्दी)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/PriyaKarmali_LanguageProficiency_V3_1.mp4?time=1638310588
italian
(italiano)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_CristianoSacchetti.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/CristianoSacchetti_LanguageProficiency_V3_1.mp4?time=1638310588
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_GiulioCattarossi.jpg?time=1638310588,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/GiulioCattarossi_LanguageProficiency_V3_1.mp4?time=1638310588
Japanese
(日本語)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/Kiyoshi_Tachikawa_v2.mp4?time=1638310588
korean
(한국어)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/JaeHeonKim_LanguageProficiency_V3_1.mp4?time=1638310588
portuguese
(Português)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/RamonDiazTrelles_LanguageProficiency_V3_1.mp4?time=1638310588
spanish
(español)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4?time=1638310588
vietnamese
(Tiếng Việt)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/HannahHuynh_LanguageProficiency_V3_1.mp4?time=1638310588

News & Events

November 22, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 8, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
October 25, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 22, 2021
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
September 22, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 8, 2021
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
September 7, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
August 9, 2021
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
August 3, 2021
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
August 2, 2021
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
August 2, 2021
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
July 28, 2021
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
July 26, 2021
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
July 6, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
June 9, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
May 10, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

LUNAR® Mechanism of Delivery